Glonghui, November 15 | Yao Ming Kangde (603259.SH) announced that the wholly-owned subsidiary wuxiPharmatechHealthcareFundil.p. (“wuxifundi”) and sofinnovaCapitalxigps.àr.l. (“General Partner”) signed a subscription agreement (“subscription agreement”), agreeing that WuxiFundi will pay SofinnovaCapitalXISCSPSicav-RAIF (“Investment Fund”) has an investment fund share of 10 million euros, accounting for about 4.40% of the investment fund share already raised (the investment fund share ratio held by WuXiFundi will be further diluted as the amount raised by the investment fund increases). As of the date of this announcement, WuxiFundi has not paid the investment amount. In the future, WuxiFundi will use its own funds to fulfill the investment payment obligation in accordance with the requirements of the subscription agreement. The investment fund mainly focuses on investing in start-ups in the life sciences sector (particularly in the biomedical and medical device industries) around the world. About 70% of the investment fund's capital is invested in start-ups within the European region, and about 30% of the capital is invested outside of Europe.
SofinnovaPartners is a well-known European biotechnology investment institution with more than 50 years of industry experience and an outstanding investment record in the European life sciences sector. The investment fund focuses on making influential investments in early-stage European biomedical companies, cultivating early-stage biotech companies to become globally competitive biotech companies through exploration and transformation of high-quality scientific research results. The fund manager has established an extensive and trustworthy network of entrepreneurs and scientists, which is highly in line with the company's strategic purpose of empowering the development of global biomedical science and promoting scientific transformation.
